Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.